NCT06561308 2025-12-01
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 2 Recruiting
Clinical Trials
7 trialsNCT06288360 2025-03-20
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Tongji Hospital
Phase 2 Recruiting
NCT06289062 2024-11-05
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06288373 2024-10-30
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Phase 2/3 Recruiting
NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04812002 2022-06-03
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Women's Hospital School Of Medicine Zhejiang University
Phase 2 Recruiting
NCT05311566 2022-04-13
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting